Cambridge, United Kingdom

Oliver Schon

USPTO Granted Patents = 12 

 

 

Average Co-Inventor Count = 5.1

ph-index = 4

Forward Citations = 30(Granted Patents)


Location History:

  • Stevenage, GB (2017 - 2018)
  • Cambridge, GB (2012 - 2023)

Company Filing History:


Years Active: 2012-2023

Loading Chart...
Loading Chart...
Loading Chart...
12 patents (USPTO):Explore Patents

Title: Oliver Schon: A Pioneering Inventor in Antibody Development

Introduction

Oliver Schon is a distinguished inventor based in Cambridge, GB, known for his significant contributions to the field of biotechnology. He holds an impressive portfolio of 12 patents, showcasing his dedication to advancing medical science through innovative solutions.

Latest Patents

His latest patents include the groundbreaking work on anti-CD73 antibodies, which specifically bind to CD73 and antagonize its function. This patent provides a comprehensive framework for the development of pharmaceutical compositions that incorporate these antibodies, nucleic acids encoding them, and methods for utilizing them to treat patients. Another notable invention is the anti-serum albumin binding variants, which involves improved variants of the anti-serum albumin immunoglobulin single variable domain DOM7h-11, as well as related ligands and drug conjugates.

Career Highlights

Throughout his career, Oliver has worked with prominent organizations in the pharmaceutical industry, including Glaxo Group Limited and GlaxoSmithKline Intellectual Property Development Limited. His experience in these companies has enabled him to bring innovative ideas from concept to reality, contributing to the advancement of pharmaceutical technologies.

Collaborations

In his pursuit of innovation, Oliver has collaborated with esteemed colleagues, including Elena De Angelis and Haiqun Liu. These partnerships have fostered a collaborative environment that encourages knowledge sharing and the exploration of new ideas, leading to impactful inventions and advancements in their field.

Conclusion

Oliver Schon's contributions to the field of antibody development reflect his commitment to innovation and improving medical treatments. With a robust patent portfolio and a track record of collaboration, he continues to be a leading figure in the biotechnology sector, pushing the boundaries of what is possible in healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…